Clover Health Q4 Preview: 38.6% Revenue Growth Expected; Shares Down 14.8%
Clover Health reported $496.7 million in Q3 revenue, up 50.1% year-over-year, added 2,903 members to reach 109,226, but full-year EBITDA guidance fell short of analysts’ forecasts. For Q4, revenue is expected to grow 38.6% year-over-year, with shares down 14.8% over the last month and an average price target of $3.23.
1. Q3 Financial Performance
Clover Health posted $496.7 million in Q3 revenue, marking a 50.1% increase year-over-year. The company added 2,903 members to reach 109,226 total, met EPS forecasts but saw full-year EBITDA guidance fall well below analyst expectations.
2. Q4 Revenue Expectations
Analysts forecast 38.6% year-over-year revenue growth in Q4, a sharp acceleration from the 7.9% gain in the same quarter last year. Estimates have remained largely unchanged over the past 30 days, reflecting confidence in continued enrollment and premium income growth.
3. Peer Comparison and Share Performance
CVS Health reported 8.2% revenue growth and Cigna 10.4% in Q4, both beating estimates and lifting their shares by 1.6% and 7.5%, respectively. Clover Health’s stock has slid 14.8% over the past month, trading near $2.01 with an average analyst target of $3.23.